Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 23, 2026
Press Release: Sanofi's amlitelimab confirms its potential in atopic dermatitis
View original at globenewswire.comPress Release: Sanofi's amlitelimab confirms its potential in atopic dermatitis Sanofi's amlitelimab confirms its potential in atopic dermatitis In the SHORE phase 3 study, amlitelimab in combination with topical therapies met all primary and key secondary endpoints at Week 24 with efficacy progressively increasing thr…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Amlitelimab was well-tolerated and the safety profile was consistent with previously reported data in SHORE and COAST 2 studies
80% confidenceThe totality of data reinforce confidence in amlitelimab's potential to deliver both Q12W dosing from the start and progressive efficacy through Week 52
80% confidenceAmlitelimab efficacy progressively increases throughout the treatment period with some patients improving as early as Week 2
80% confidenceThese results validate amlitelimab's novel mechanism of action to block OX40-ligand without T-cell depletion and its promise to normalize the immune system over time
80% confidence